Ohashi Kazuo, Park Frank, Kay Mark A
Department of Pediatrics, Stanford University, Stanford, CA 94305, USA.
Hum Gene Ther. 2002 Mar 20;13(5):653-63. doi: 10.1089/10430340252837242.
Lentiviral vectors have been used for gene transfer into the liver, but the ability of these vectors to efficiently transduce quiescent hepatocytes remains controversial. Regardless, lentivirus-mediated gene transfer is greatly enhanced when delivered during hepatocellular cycling. For this reason, the present study was designed to determine the role of hepatocyte proliferation in the enhancement of lentiviral transduction by using three different modes of liver regeneration: (1) compensatory regeneration stimulated by two-thirds partial hepatectomy, (2) direct hyperplasia after intragastric administration of the primary mitogen 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP), and (3) a combination of modes 1 and 2. Vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped lentiviral vector expressing beta-galactosidase was administered to mice via the peripheral circulation after a regeneration stimulus. Gene transfer as measured by 5-bromo-4-chloro-3-indolyl-beta-D-galactoside (X-Gal) staining showed 30-fold higher levels of liver transduction in groups 1 and 2 as compared with the non-liver-manipulated control group (p < 0.005). The combination of TCPOBOP and partial hepatectomy (group 3) resulted in an ~80-fold increase in transduction efficiency compared with the control animals. The enhanced transduction was consistent with higher levels of hepatocellular proliferation observed in animals that received both treatments compared with either single treatment alone. Importantly, the hepatocytes were the predominant cell type transduced, although transgene expression was observed in a low number of nonparenchymal cells regardless of which liver stimulus was received. Biodistribution studies confirmed that most of the gene transfer was limited to the liver and spleen. Taken together, this study suggests that disease-induced cellular proliferation in the liver will enhance the utility of this vector in treating diseases such as viral hepatitis, liver cirrhosis, and cancer.
慢病毒载体已被用于将基因导入肝脏,但这些载体有效转导静止肝细胞的能力仍存在争议。无论如何,当在肝细胞周期中进行递送时,慢病毒介导的基因转移会大大增强。因此,本研究旨在通过三种不同的肝脏再生模式来确定肝细胞增殖在增强慢病毒转导中的作用:(1)三分之二部分肝切除刺激的代偿性再生,(2)胃内给予主要促有丝分裂原1,4-双[2-(3,5-二氯吡啶氧基)]苯(TCPOBOP)后的直接增生,以及(3)模式1和模式2的组合。在再生刺激后,通过外周循环将表达β-半乳糖苷酶的水疱性口炎病毒糖蛋白(VSV-G)假型慢病毒载体给予小鼠。通过5-溴-4-氯-3-吲哚基-β-D-半乳糖苷(X-Gal)染色测量的基因转移显示,与未进行肝脏操作的对照组相比,第1组和第2组的肝脏转导水平高30倍(p < 0.005)。与对照动物相比,TCPOBOP和部分肝切除的组合(第3组)导致转导效率增加约80倍。增强的转导与在接受两种治疗的动物中观察到的较高水平的肝细胞增殖一致,而单独接受任何一种单一治疗的动物则不然。重要的是,肝细胞是被转导的主要细胞类型,尽管无论接受哪种肝脏刺激,在少量非实质细胞中都观察到了转基因表达。生物分布研究证实,大多数基因转移仅限于肝脏和脾脏。综上所述,本研究表明,肝脏中疾病诱导的细胞增殖将增强该载体在治疗病毒性肝炎、肝硬化和癌症等疾病中的效用。